2025 Maruti Suzuki Grand Vitara S-CNG launched with standard 6 airbags
Commenting on the launch, Partho Banerjee, Senior Executive Officer, Marketing and Sales, Maruti Suzuki India Limited, said, "The new 2025 Grand Vitara S-CNG offers a range of new convenience & safety alongside the introduction of 6 airbags as standard. Powered by our Next-Gen K-series 1.5-litre Dual Jet Dual VVT engine, it delivers remarkable fuel-efficiency, without compromising on its exhilarating SUV drive experience. We are confident that the new Grand Vitara S-CNG will continue to win the hearts of customers with its robust safety and commendable efficiency."The SUV now boasts features such as a PM 2.5 air purifier with display, ventilated front seats, rear door sunshades, wireless charging dock, and a premium sound system by Clarion. Technology enhancements include a 9-inch SmartPlay Pro+ infotainment system with wireless connectivity, TPMS, Suzuki Connect, and a rearview camera.advertisementOn the safety front, in addition to six airbags, the SUV is equipped with ESP with Hill Hold Assist, ABS with EBD, ISOFIX child seat mounts, and front and rear disc brakes.The Grand Vitara S-CNG is priced at Rs 13.48 lakh for the Delta variant and Rs 15.62 lakh for the Zeta variant (both ex-showroom, Delhi).Subscribe to Auto Today Magazine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
37 minutes ago
- Hans India
Indices tumble nearly 1% on selling in IT, auto stocks
Equity benchmark indices Sensex and Nifty declined for the third session in a row on Friday, dropping nearly 1 per cent, dragged by heavy selling in IT, auto and energy stocks amid a muted start of the earnings season. Tariff-related uncertainties and mixed global market trends also added to the pressure, analysts said. The 30-share BSE Sensex tanked 689.81 points or 0.83 per cent to settle at 82,500.47. During the day, it fell 748.03 points or 0.89 per cent to 82,442.25. As many as 2,450 stocks declined while 1,557 advanced and 158 remained unchanged on the BSE. Similarly, the 50-share NSE Nifty dropped 205.40 points or 0.81 per cent to 25,149.85. On the weekly front, the BSE benchmark dropped 932.42 points or 1.11 per cent, and the Nifty tanked 311.15 points or 1.22 per cent. 'While weak European market cues and negative US Dow Futures weighed on sentiment, the disappointing start to earnings season by software major TCS cautioned investors about the sluggish global demand scenario that led to heavy selling in IT, telecom, auto, realty and oil & gas stocks,' Prashanth Tapse, Senior VP (Research), Mehta Equities Ltd, said. From the Sensex firms, Tata Consultancy Services declined 3.46 per cent after reporting its June quarter earnings. The country's largest IT services company on Thursday reported a 6 per cent growth in June quarter net profit at Rs 12,760 crore, helped by a jump in non-core income even as revenues grew at a tepid pace. The rupee revenue grew 1.3 per cent to Rs 63,437 crore during the quarter. Still, it was down by over 3 per cent on a constant currency basis, as the company faced headwinds in its major markets amid a winding down of the BSNL deal, which helped it in recent quarters. Mahindra & Mahindra, Bharti Airtel, Tata Motors, Titan, HCL Tech, Bajaj Finance, Reliance Industries, Trent, Infosys and HDFC Bank were among the other major laggards from the pack.
News18
an hour ago
- News18
'Pulp Fiction? Not Quite': How Indian Oranges Are Powering A French Medicine To Treat Varicose Veins
'We are proud that the oranges grown in Indian soil are now an integral part of a medicine used by millions across the world," Aurelien Breton, managing director, Servier India, told News18. 'We procure oranges from Maharashtra, Telangana, Andhra Pradesh, MP, and Rajasthan currently." According to IQVIA data, Daflon's 500mg and 1000mg stand at a value of Rs 61 crore as per moving annual turnover, May 2025, ranking 2nd in the varicose therapy market. The average number of patients treated in a month is 1.2 lakhs. The citrus supply chain The Indian-sourced oranges are first processed locally—cleaned, dried, and converted into powder form. This citrus powder is then exported to Servier's manufacturing headquarters in France, where it undergoes sophisticated processing to extract the active pharmaceutical ingredients (APIs). Interestingly, those APIs are then re-imported back to India, where the final formulation of Daflon is completed for domestic distribution. This circular, transcontinental journey of a single orange—from a farm in Nagpur to a lab in northern France and back to a pharmacy shelf in Delhi—highlights the globalisation of pharmaceutical supply chains and India's growing importance as a trusted sourcing and manufacturing hub. The move wasn't just about logistics or cost-efficiency. According to Breton, Indian oranges matched the quality standards required for flavonoid extraction. 'We achieved 100% reliance on local Indian oranges through our Indian supply chain with effect from the financial year 2021." Indian oranges matched the former Spanish and Mexican counterparts. '2000 metric tons of small oranges were procured in the financial year 2023-24. We work with aggregators and farmers in multiple states in India," said Breton. Company set to bring precision cancer medicine Servier Pharma is set to bring precision cancer treatments to India. 'Unlike traditional chemotherapy, these therapies act on specific genetic mutations that are responsible for causing the cancer," Breton said. Out of three novel drugs coming into the Indian market, the first drug, Ivosidenib, targets a mutated protein known as isocitrate dehydrogenase 1 (IDH1), which is found in a subset of patients with cholangiocarcinoma (a type of biliary tract cancer) and acute myeloid leukemia (a form of blood cancer). 'Epidemiological data show a high prevalence of biliary tract cancers along the Ganga River basin, supporting the need for this targeted option, which can significantly delay disease progression. In clinical trials, Ivosidenib has demonstrated more than a threefold improvement in survival for AML (blood cancer) patients." The drug was officially launched in India in June 2025.
Hans India
an hour ago
- Hans India
AP Chambers seeks a ban on export of raw human hair
Vijayawada: The Andhra Pradesh Chambers of Commerce and Industry Federation (AP Chambers) has submitted a detailed representation to Chief Minister Nara Chandrababu Naidu urging his personal intervention to stop the export of raw human hair, especially non-Remy (comb waste/GAoli/Chutti) hair, to safeguard the domestic human hair industry. In the representation, AP Chambers' president Potluri Bhaskara Rao and general secretary B Rajasekhar highlighted that in the last 20 years, the demand for Non-Remy Hair had gone up exponentially and Chinese buyers were buying huge quantities till 2012-13 from Indian exporters. But in the last 10 years, China has started reducing legal imports by smuggling Non-Remy (Comb Waste Hair) through Myanmar, Bangladesh, and Nepal where it is processed with child labour and again smuggled to China across border to avoid duties. Despite an earlier ban imposed in March 2022 by DGFT, exports resumed shortly after, including by previously blacklisted traders. Non-Remy Hair forms 85 percent of total exports and only 15 percent of hair is Remy Hair, sourced from temples, which is sold in auction/direct sales by temples. They pointed out that the Indian Human Hair Extension and Wig industry, currently valued at Rs 8,000 crore, has the potential to grow to Rs 30,000 crore in the next decade. The industry, which has a major presence in Madepalli and Eluru, provides employment to over 10 lakh women across rural India. AP Chambers also made key suggestions including the export of raw human hair having ITC (HS) Code 05010010 should be strictly prohibited to make it available for Indian hair processors for value-addition, Remy-type hair from temples should not be sold to China or Chinese agents, restrict temple hair auctions only to registered manufacturers/exporters and not to illegal trader to support 'Make it India' initiative of the Union government, establishment of a dedicated research chair for human hair at IIT Chennai to foster R & D, reduction of duties on human hair imported by countries wherever India has any bilateral agreements, incentives or subsidies to hair exported to African countries as they are the biggest consumers of hair and wigs as they will help boost the exports to African countries. Bhaskara Rao emphasised that this is a unique industry that transforms waste into valuable foreign exchange while empowering lakhs of women through rural employment. He requested the Chief Minister to take up the matter with the Union Minister of Commerce & Industry Piyush Goyal to ensure the long-term sustainability and growth of the human hair industry in Andhra Pradesh and India.
